argenx NV ADR (ARGX)vsMesoblast Ltd (MESO)
ARGX
argenx NV ADR
$782.17
-0.65%
HEALTHCARE · Cap: $49.20B
MESO
Mesoblast Ltd
$14.74
-0.41%
HEALTHCARE · Cap: $1.91B
Smart Verdict
WallStSmart Research — data-driven comparison
argenx NV ADR generates 7153% more annual revenue ($4.74B vs $65.38M). ARGX leads profitability with a 31.4% profit margin vs -144.3%. ARGX earns a higher WallStSmart Score of 75/100 (B).
ARGX
Strong Buy75
out of 100
Grade: B
MESO
Avoid25
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+64.2%
Fair Value
$2329.77
Current Price
$782.17
$1547.60 discount
Margin of Safety
+45.7%
Fair Value
$33.69
Current Price
$14.74
$18.95 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Keeps 31 of every $100 in revenue as profit
Strong operational efficiency at 30.0%
Revenue surging 62.6% year-over-year
Earnings expanding 114.0% YoY
Safe zone — low bankruptcy risk
Every $100 of equity generates 20 in profit
Revenue surging 1527.0% year-over-year
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Trading at 165.4x book value
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -18.2% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : ARGX
The strongest argument for ARGX centers on Profit Margin, Operating Margin, Revenue Growth. Profitability is solid with margins at 31.4% and operating margin at 30.0%. Revenue growth of 62.6% demonstrates continued momentum.
Bull Case : MESO
The strongest argument for MESO centers on Revenue Growth. Revenue growth of 1527.0% demonstrates continued momentum.
Bear Case : ARGX
The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, Price/Book.
Bear Case : MESO
The primary concerns for MESO are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
ARGX profiles as a growth stock while MESO is a hypergrowth play — different risk/reward profiles.
MESO carries more volatility with a beta of 0.79 — expect wider price swings.
MESO is growing revenue faster at 1527.0% — sustainability is the question.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ARGX scores higher overall (75/100 vs 25/100), backed by strong 31.4% margins and 62.6% revenue growth. MESO offers better value entry with a 45.7% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Mesoblast Ltd
HEALTHCARE · BIOTECHNOLOGY · USA
Mesoblast Limited, a biopharmaceutical company, develops and markets allogeneic cellular drugs. The company is headquartered in Melbourne, Australia.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?